Francis Ann, Erridge Simon, Holvey Carl, Coomber Ross, Guru Rahul, Darweish Medniuk Alia, Sajad Mohammed, Searle Robert, Usmani Azfer, Varma Sanjay, Rucker James, Platt Michael, Holden Wendy, Sodergren Mikael H
Department of Surgery and Cancer, Medical Cannabis Research Group, Imperial College London.
Department of Medicine, Curaleaf Clinic.
Int Clin Psychopharmacol. 2025 Jul 1;40(4):242-249. doi: 10.1097/YIC.0000000000000556. Epub 2024 Jul 2.
The aim of this study was to assess changes in validated patient-reported outcome measures after initiation of cannabis-based medicinal products (CBMPs) and the safety of CBMPs in patients with inflammatory arthritis. A prospective case series from the UK Medical Cannabis Registry was analyzed. The primary outcomes changes were in Brief Pain Inventory, McGill Pain Questionnaire, EuroQol 5-dimension 5-level (EQ-5D-5L), Generalised Anxiety Disorder-7 questionnaire, and Single-Item Sleep Quality Scale at 1, 3, 6, and 12 months of follow-up compared with baseline. Adverse events were analyzed in accordance with Common Terminology Criteria for Adverse Events, v.4.0. Statistical significance was defined as a P -value less than 0.050. Eighty-two patients met the inclusion criteria. Initiation of CBMP treatment was associated with improvements in Brief Pain Inventory, McGill Pain Questionnaire, EQ-5D-5L, Generalised Anxiety Disorder-7 questionnaire, and Single-Item Sleep Quality Scale at 1, 3, 6, and 12 months compared with baseline ( P < 0.050). There were 102 (44.35%) mild adverse events, 97 (42.17%) moderate adverse events, and 31 (13.48%) severe adverse events recorded by 21 (25.61%) participants. This study suggests that CBMP treatment is associated with pain improvement and increased health-related quality of life for inflammatory arthritis patients. While causality cannot be inferred in this observational study, the results support the development of randomized control trials for inflammatory arthritis pain management with CBMPs.
本研究的目的是评估基于大麻的药用产品（CBMPs）开始使用后经过验证的患者报告结局指标的变化，以及CBMPs在炎性关节炎患者中的安全性。对来自英国医用大麻登记处的一项前瞻性病例系列进行了分析。主要结局变化为随访1、3、6和12个月时与基线相比的简明疼痛量表、麦吉尔疼痛问卷、欧洲五维健康量表（EQ-5D-5L）、广泛性焦虑障碍7项问卷和单项睡眠质量量表。按照不良事件通用术语标准第4.0版对不良事件进行分析。统计学显著性定义为P值小于0.050。82名患者符合纳入标准。与基线相比，在1、3、6和12个月时，开始使用CBMP治疗与简明疼痛量表、麦吉尔疼痛问卷、EQ-5D-5L、广泛性焦虑障碍7项问卷和单项睡眠质量量表的改善相关（P ＜0.050）。21名（25.61%）参与者记录到102起（44.35%）轻度不良事件、97起（42.17%）中度不良事件和31起（13.48%）重度不良事件。本研究表明，CBMP治疗与炎性关节炎患者的疼痛改善及健康相关生活质量提高相关。虽然在这项观察性研究中无法推断因果关系，但结果支持开展关于使用CBMPs治疗炎性关节炎疼痛的随机对照试验。
